PharmaJet®, a company dedicated to enhancing the delivery and effectiveness of injectable medicines through its needle-free technology, has announced a new Distribution Agreement with ATR, an affiliate of EVA Pharma, a leading pharmaceutical organisation advancing healthcare access and innovation across the Middle East and Africa. The agreement was formalised in Frankfurt during the CPHI event on 30 October 2025, and includes technology transfer, distribution of the Tropis® system, and local manufacturing support.
The collaboration is designed to expand access to needle-free vaccination in Egypt and the wider region, while strengthening Egypt’s domestic manufacturing capabilities. PharmaJet’s Tropis intradermal needle-free delivery system offers significant advantages for routine immunisation programmes, including reduced polio vaccination costs1, lowered vaccine hesitancy2,3, improved coverage3, and opportunities for regional production of medical technology. The agreement builds upon an MOU signed in July 2025 between PharmaJet, Egypt’s Unified Procurement Agency (UPA), and EVA Pharma, which outlined opportunities for integrating Tropis into UPA’s supply portfolio.
Introducing Tropis into national immunisation programmes aligns closely with Egypt’s “1000 Golden Days” initiative, which focuses on maternal and infant health from pregnancy to a child’s second birthday. The partnership is expected to reduce overall immunisation expenditure while improving vaccination acceptance. In the longer term, Tropis manufacturing and additional needle-free product development may support future vaccination needs and bolster epidemic and pandemic preparedness.
EVA Pharma is one of the region’s leading pharmaceutical and medical device producers, with extensive experience in manufacturing and distributing medicines. “This collaboration puts children first,” said Riad Armanious, CEO of EVA Pharma. “We’re reimagining vaccination through local innovation that improves every child’s experience while empowering healthcare professionals. By localizing manufacturing, we expand access and use existing budgets to reach many more children in Africa sustainably.”
“We are proud to collaborate with ATR and EVA Pharma to localize needle-free manufacturing and delivery,” said Paul LaBarre, Senior Vice President of Business Development for PharmaJet. “This partnership represents a strategic step forward for PharmaJet in the Middle East and Northern Africa region. Working with these innovative teams will accelerate integration of needle-free intradermal vaccine delivery into routine immunization programs in Egypt and beyond.”
